ArticleJournal of immunotherapy (Hagerstown, Md. : 1997)2009
No correlation between clinical response to CTLA-4 blockade and presence of NY-ESO-1 antibody in patients with metastatic melanoma.
Article in Journal of immunotherapy (Hagerstown, Md. : 1997), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Trial
- Tumorous expression of NAC1 restrains antitumor immunity through the LDHA-mediated immune evasion.Journal for immunotherapy of cancer · 2022Article
- B cells and antibody production in melanoma.Mammalian genome : official journal of the International Mammalian Genome Society · 2018Review
- Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma.Journal of translational medicine · 2018Article
- NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.Frontiers in immunology · 2018Review
- Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition.Current oncology reports · 2016Review
- Novel technologies and emerging biomarkers for personalized cancer immunotherapy.Journal for immunotherapy of cancer · 2016Review
- Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1.Frontiers in immunology · 2014Review
- At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.Journal of leukocyte biology · 2013Review
- Unmasking the immune recognition of prostate cancer with CTLA4 blockade.Nature reviews. Cancer · 2012Review
- Drug targets and predictive biomarkers in the management of metastatic melanoma.Pharmacogenomics and personalized medicine · 2012Article
- Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
Corrections and comments
- Comment on
Authors and funding
4 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.